If you have prostate cancer, germline testing looks for inherited genetic changes, while tumour testing looks for changes within the cancer itself. For you, germline results may be important for your family, while tumour results can help identify treatment-relevant changes in your cancer.
Sometimes both tests find the same change, such as BRCA2. For you, a tumour result does not automatically mean you inherited it, so a blood or saliva test may be needed to confirm this.
What Is Germline Genetic Testing?
If you have prostate cancer, germline testing looks for inherited changes in your DNA that you have carried since birth. Testing usually uses a blood sample, although saliva may sometimes be used. In the current NHS England R430 inherited prostate cancer pathway, the signed-off panel includes genes such as BRCA1, BRCA2, ATM, CHEK2, PALB2 and the mismatch-repair genes MLH1, MSH2 and MSH6.
The result can clarify inherited cancer risk and, in advanced prostate cancer, may affect eligibility for some targeted treatments. It can also be important for your family because an inherited variant may be passed to your children, brothers, sisters or other blood relatives.
What Is Somatic or Tumour Genetic Testing?
Tumour testing looks for genetic changes within the cancer itself. For you, testing may use tumour tissue from a biopsy or surgery, or in selected situations a blood sample containing circulating tumour DNA.
The result can help your specialist understand which treatments may suit your cancer. For you, a BRCA1 or BRCA2 finding may point towards targeted treatment, but it does not automatically mean that you inherited the change.
Germline vs Tumour Genetic Testing
| Feature | Germline testing | Tumour testing |
| What it looks for | Inherited variants present throughout the body | Genetic alterations within the cancer |
| Main sample | Usually blood; saliva may be used in some germline-testing settings | Usually tumour tissue |
| Main question | Is there an inherited cancer predisposition? | Does the cancer carry a treatment-relevant alteration? |
| Can affect treatment? | Yes, in some advanced prostate cancers | Yes, particularly when testing for treatment biomarkers |
| Can affect relatives? | Yes | Not unless germline origin is confirmed |
| BRCA1/2 can appear? | Yes | Yes |
| Negative result meaning | No pathogenic inherited variant found in genes tested | No relevant tumour alteration detected in tested sample |
| If tumour BRCA is positive | — | Germline confirmation may be needed |
| Typical NHS pathways | R430, R208, R240, R444.2 | M218.1 for eligible metastatic castration-resistant prostate cancer, plus other relevant cancer-directory tests |
Why Can the Same Gene Appear on Both Tests?
If your tumour test finds a pathogenic BRCA2 alteration, it may be inherited or may have arisen only within your cancer. A germline blood or saliva test can help your specialist tell the difference.
A tumour-only BRCA2 result may help guide your cancer treatment, while a confirmed inherited result can also be relevant to your children, brothers, sisters and other relatives. For you, this is why the same gene can appear on both reports but have different meanings.
What Type of Sample Is Used for Each Test?

Germline and tumour genetic testing may use different samples because they are looking for different types of genetic changes.
- Blood for germline testing: A blood sample is commonly used to look for inherited genetic changes present throughout your body.
- Saliva may also be used: In some germline-testing settings, saliva can provide the DNA needed for testing.
- Tumour tissue for somatic testing: Cancer tissue from a biopsy or surgery is commonly used to look for genetic alterations within the tumour.
- Blood can also test tumour DNA: In some situations, a blood sample can be used to look for circulating tumour DNA released by the cancer.
Even when both tests involve blood, one may be analysing inherited DNA while the other is looking for DNA from the cancer.
Who Is More Likely to Need Germline Testing?
If you are being assessed through the NHS in England, whether you are offered germline testing will depend on your age at diagnosis, cancer stage, ancestry and family history. You may be more likely to qualify if you were diagnosed with prostate cancer before age 50, metastatic prostate cancer before age 60, meet certain ancestry criteria, or if your family history suggests a higher chance of an inherited pathogenic variant.
You may also be offered testing if your tumour test finds a variant that could be inherited or if BRCA testing is needed for an eligible treatment pathway. Your specialist can check the current National Genomic Test Directory to confirm which pathway applies to you.
UK Guidance Note
The NHS National Genomic Test Directory separates rare and inherited-disease testing from cancer genomic testing and defines which tests are commissioned and who is eligible. For you, the current criteria should always be checked because different parts of the directory are updated separately.
For prostate cancer, constitutional routes can include R430 inherited prostate cancer, R208 for relevant BRCA-related family histories, R240 for germline confirmation of a tumour variant and R444.2 for PARP-eligible mCRPC when R208/R430 criteria are not met and either there is insufficient tumour tissue or M218.1 tumour testing has failed. Somatic BRCA testing for eligible mCRPC is available through M218.1.
Who Is More Likely to Need Tumour Genomic Testing?
International guidance supports tumour genomic testing in metastatic prostate cancer because genomic findings can affect treatment and clinical-trial options. NHS England commissioning pathways are more specific.
In the current NHS pathway, M218.1 tumour testing looks for BRCA1 and BRCA2 alterations in people with metastatic castration-resistant prostate cancer who may be eligible for PARP-inhibitor treatment. Other tumour genomic tests may be available for particular clinical indications or through clinical trials, so your specialist will consider your cancer stage and the decision the test is intended to inform.
What Is Homologous Recombination Repair and Why Is It Important?
Homologous recombination repair (HRR) is one of the ways your cells repair damaged DNA. For you, pathogenic alterations in genes such as BRCA1 or BRCA2 can impair DNA repair and may make PARP-based treatment relevant in defined settings.
An HRR change can be inherited or develop only within your cancer. For you, both can potentially matter when choosing treatment, but only a confirmed inherited change can indicate a hereditary risk that may also be relevant to your close relatives.
Research Insight
A 2025 ASCO guideline reviewed evidence on germline and somatic genomic testing in metastatic prostate cancer and recommended both types of DNA sequencing because they answer different clinical questions. Germline testing can identify inherited cancer risk and implications for relatives, while somatic testing can identify cancer-specific alterations that may influence treatment.
The NHS England pathway is more specific about which tests are commissioned for particular situations, so international recommendations and NHS test eligibility should not be treated as identical.
How Can Genetic Results Affect Treatment With PARP Inhibitors?

If your prostate cancer has a relevant DNA-repair change, your specialist may consider a PARP inhibitor. BRCA1 or BRCA2 results can be particularly important because eligibility for some PARP-based treatments depends on specific genomic findings.
Your exact treatment options will depend on the gene involved, your previous treatments and the current NHS guidance. This means a genetic result can help your specialist decide whether a PARP-based treatment is an appropriate option.
Clinical Tip
Before testing, ask your specialist what decision the result is intended to inform.
A BRCA result may be sought primarily to determine whether a treatment is appropriate, to assess inherited risk for you and your relatives, or for both purposes. Knowing the purpose helps explain why one patient may need tumour testing, another germline testing, and some patients need both.
Can Germline Testing Affect Treatment Even Though It Is an Inherited-Risk Test?
Yes. If you carry an inherited change such as BRCA2, the result may help your specialist understand whether your cancer has a DNA-repair weakness that could be relevant to treatment. For you, this means germline testing can sometimes help guide treatment as well as assess risks for your family.
A genetic result does not decide your treatment on its own. For you, your cancer stage, previous treatments, overall health and the specific treatment available through the NHS will all be considered alongside the genetic result.
Can Tumour Testing Tell Your Children Whether They Are at Risk?
Not on its own. If your tumour test finds a pathogenic BRCA2 or other cancer-associated alteration, it does not automatically mean that you inherited it. For you, a separate germline test using blood or saliva may be needed to confirm whether the change is present in your normal DNA.
If the change is confirmed as inherited, it may be relevant to your children, brothers, sisters and other blood relatives. Genetic counselling can explain whether relatives should consider testing and what the result could mean for them.
What Does a Negative Germline Test Mean If the Tumour Has a Mutation?
If your tumour has a pathogenic BRCA2 alteration that is not found on germline testing, it is likely to be a somatic tumour-only finding. For you, it may still be relevant to treatment, but it would not usually mean that your children or other relatives inherited that specific change.
A negative germline result does not completely rule out inherited risk. For you, your family history can still be important, especially when several relatives have had prostate or related cancers, so your specialist may consider the wider family pattern as well.
What Does a Variant of Uncertain Significance Mean?

If your genetic test finds a variant of uncertain significance, or VUS, it means a DNA change has been found but cannot yet be classified as benign or pathogenic. For you, this does not confirm an inherited cancer risk.
A VUS may be reclassified as more scientific evidence becomes available. For you, your treatment or family testing should not usually be changed based on a VUS alone, and your genetics team can explain whether it needs reviewing later.
Why Can a Tumour Test Sometimes Fail?
If your tumour genetic test fails, it does not necessarily mean your cancer has no genetic changes. For you, the sample may not contain enough suitable tumour DNA or may be technically difficult to analyse.
Your specialist may use another tissue sample or a blood test instead. For you, the choice will depend on what tissue is available and whether another biopsy is necessary.
What Is a Liquid Biopsy?
If your specialist offers you a liquid biopsy, they are using a blood sample to look for small pieces of DNA released by your prostate cancer. For you, this can be useful when there is not enough suitable tumour tissue for genetic testing.
It is different from a standard germline blood test. For you, liquid biopsy looks for DNA from the cancer, while germline testing looks for inherited genetic changes. Your specialist can explain which test you need and what they hope the result will show.
Why Does Mismatch-Repair Testing Matter?
If your prostate cancer has a mismatch-repair abnormality, your specialist may look more closely at your tumour genetics. For you, pathogenic mismatch-repair alterations can affect treatment assessment and may also raise the possibility of Lynch syndrome.
These changes can also be inherited through Lynch syndrome. For you, a tumour finding may therefore lead to further genetic testing to see whether the change is inherited and whether your relatives may also need genetic advice.
Evidence Note
A negative tumour test does not replace germline testing when you independently meet constitutional-testing criteria. For you, tumour and germline assays have different technical scopes, so one negative result cannot always substitute for the other test.
Conversely, germline testing alone cannot reveal all cancer-acquired alterations. This is why tumour and germline testing should be viewed as complementary tests addressing different clinical questions rather than interchangeable versions of the same analysis.
What Should You Ask Before Having Genetic Testing?

Before you have genetic testing, ask your specialist which test you are being offered and why. For you, it may be a germline test, tumour test or both, using blood, saliva or tumour tissue.
Ask what the result could change for you and your family, and what happens if the result is negative or uncertain. If you are in England, you can also ask whether you meet the current NHS genetic-testing criteria.
Myth vs Fact
| Myth | Fact |
| Germline and tumour testing are the same test. | They analyse different DNA sources and answer different questions. |
| A BRCA2 alteration in the tumour must be inherited. | It can be somatic only; constitutional testing may be needed. |
| A negative tumour test means inherited BRCA risk is ruled out. | No. Germline testing may still be needed if constitutional criteria are met. |
| Every metastatic prostate cancer needs the same genomic test. | International guidelines recommend both germline and somatic sequencing in metastatic prostate cancer, but NHS England testing follows specific eligibility criteria and test pathways. |
| Any HRR-gene alteration guarantees a PARP inhibitor will work. | Treatment eligibility depends on the gene, stage, previous therapy and NICE indication. |
| A liquid biopsy is just a germline blood test. | No. ctDNA looks for cancer-derived DNA; germline testing looks at constitutional DNA. |
| Liquid biopsy routinely replaces tumour tissue in NHS prostate cancer testing. | Not currently as a general national prostate-cancer pathway. |
| A VUS is a positive genetic test. | No. It is uncertain and is not clinically actionable by itself. |
| Tumour testing can tell children whether they inherited a mutation. | Germline confirmation is needed before drawing inherited-risk conclusions. |
| Only BRCA genes matter. | Mismatch-repair and other pathways can also be clinically relevant. |
Key Takeaways
- Germline testing looks for inherited constitutional variants.
- Tumour testing looks for genetic alterations within the cancer.
- The same gene, including BRCA1 or BRCA2, can appear on both tests.
- A tumour BRCA result does not automatically mean it was inherited.
- R240 can be used to establish whether a pathogenic tumour variant is germline.
- Current NHS England constitutional pathways include R430, R208, R240 and R444.2.
- Current tumour BRCA testing for eligible mCRPC patients is available through M218.1.
- R430 includes defined criteria such as prostate cancer before age 50, metastatic disease before age 60 and qualifying family-history or ancestry criteria.
- Tumour and germline testing can both influence treatment, but only germline testing establishes inherited family risk.
Frequently Asked Questions
1. What Is the Difference Between Germline and Tumour Genetic Testing?
Germline testing looks for inherited genetic changes that you have carried since birth, usually using blood or saliva. Tumour testing looks for genetic changes within your prostate cancer and may use tumour tissue or a blood test for circulating tumour DNA.
2. Can the Same Gene Appear on Germline and Tumour Genetic Tests?
Yes. Genes such as BRCA1 and BRCA2 can appear on both tests, but a tumour finding does not automatically mean you inherited the change. A germline test can help confirm whether the change is present in your normal DNA.
3. Who Is More Likely to Need Germline Genetic Testing?
NHS germline-testing eligibility depends on your age at diagnosis, cancer stage, ancestry, family history and whether a tumour finding needs germline confirmation. For example, current R430 criteria include metastatic prostate cancer diagnosed before age 60. Your specialist should use the current National Genomic Test Directory to confirm eligibility.
4. Who Is More Likely to Need Tumour Genomic Testing?
Tumour genomic testing may be useful when the result could affect treatment or clinical-trial options. In the current NHS England pathway, M218.1 BRCA1/BRCA2 tumour testing is used for eligible people with metastatic castration-resistant prostate cancer being considered for PARP-inhibitor treatment. Other tests may apply in specific circumstances.
5. What Is the Difference Between an Inherited and Tumour-Only Genetic Change?
An inherited genetic change is present throughout your body and may also be relevant to your blood relatives. A tumour-only change develops within the cancer itself and does not automatically mean that your children or other relatives have inherited it.
6. Can Genetic Testing Affect Prostate Cancer Treatment?
Yes. Genetic results can sometimes help your specialist identify treatment options, including certain PARP inhibitors when relevant DNA-repair changes such as BRCA1 or BRCA2 are present. Your cancer stage, previous treatments, overall health and available NHS treatments will also be considered.
7. What Does a Negative Germline Test Mean If Your Tumour Has a Mutation?
If your tumour has a BRCA2 change but your germline test does not, the change is likely to have developed only within the cancer. It may still be relevant to your treatment, but it would not usually mean that your children or other relatives inherited that specific change.
8. What Is a Variant of Uncertain Significance?
A variant of uncertain significance (VUS) is a DNA change whose effect is not yet known. It does not confirm an inherited cancer risk, and treatment or family testing should not usually be changed based on a VUS alone.
9. What Is a Liquid Biopsy for Prostate Cancer?
A liquid biopsy uses a blood sample to look for small pieces of DNA released by your prostate cancer. Unlike a standard germline blood test, it looks for DNA from the cancer rather than inherited genetic changes.
10. What Should You Ask Before Having Genetic Testing?
Ask your specialist whether you are being offered germline testing, tumour testing or both, and why the test is recommended. You should also ask what the result could mean for your treatment and family, including what happens if the result is negative or uncertain.
Final Thoughts: What Should You Know About Germline and Tumour Genetic Testing?
Germline and tumour genetic testing look for different types of genetic changes, but both can provide useful information when planning prostate cancer treatment. Your specialist may recommend one or both tests depending on your cancer, family history and whether the results could affect your treatment or provide information for your relatives.
If you would like specialist advice about prostate cancer genetic testing, you can contact Prostate Clinic London to discuss which assessment may be appropriate for you.
References:
- NHS England (2026) ‘National genomic test directory’. Page updated 16 July 2026. Available at: https://www.england.nhs.uk/publication/national-genomic-test-directories/
- National Institute for Health and Care Excellence (2023) ‘Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer’. Technology appraisal guidance TA887. Published 10 May 2023. Available at: https://www.nice.org.uk/guidance/ta887
- Yu, E.Y., Rumble, R.B., Agarwal, N., Cheng, H.H., Eggener, S.E., Bitting, R.L., Beltran, H., Giri, V.N., Spratt, D., Mahal, B., Lu, K., Crispino, T. and Trabulsi, E.J. (2025) ‘Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline’, Journal of Clinical Oncology, 43(6), pp. 748–758. Available at: https://pubmed.ncbi.nlm.nih.gov/39787437/
- Truong, H., Breen, K., Nandakumar, S., Sjoberg, D.D. et al. (2023) ‘Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer’, European Urology, 83(1), pp. 29–38. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10208030/
- Giri, V.N., Knudsen, K.E., Kelly, W.K. et al. (2020) ‘Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019’, Journal of Clinical Oncology, 38(24), pp. 2798–2811. Available at: https://pubmed.ncbi.nlm.nih.gov/32516092/
- Russo, J. and Giri, V.N. (2022) ‘Germline testing and genetic counselling in prostate cancer’, Nature Reviews Urology, 19(6), pp. 331–343. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9022414/
- de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K.N., Sartor, O., Agarwal, N., Olmos, D., Thiery-Vuillemin, A., Twardowski, P., Mehra, N., Goessl, C., Kang, J., Burgents, J., Wu, W., Kohlmann, A., Adelman, C.A. and Hussain, M. (2020) ‘Olaparib for Metastatic Castration-Resistant Prostate Cancer’, New England Journal of Medicine, 382(22), pp. 2091–2102. Available at: https://pubmed.ncbi.nlm.nih.gov/32343890/